文献速递肝病

失代偿患者一年内因病情改善和再代偿而从肝移植名单中移除

Delisting From Liver Transplant List for Improvement and Recompensation Among Decompensated Patients at One Year.
PubMed 文献 · Am J Gastroenterol · 2024-12-23

基于美国器官共享联合网络数据库的回顾性队列(2002-2022年)分析了120451例成人肝移植等待者,7196例(6.2%)因肝病改善被移除,酒精相关肝病和乙肝最常见;5750例失代偿者中567例(9.9%)出现再代偿,乙肝病因最易再代偿(OR 2.37)。

要点

  • 成人肝移植等待者中6.2%因肝病改善被移除,三个时间段分别为5.6%、7.2%、5.3%。
  • 酒精相关肝病和乙肝是移除最常见病因,一年累积发生率分别为1.18和1.17。
  • 失代偿者移除后再代偿率9.9%,乙肝病因再代偿可能性最高(OR 2.37)。

核心结论

  • 酒精相关肝病和乙肝是因肝病改善而移除肝移植名单的最常见病因,约10%的移除患者出现再代偿,乙肝病因最可能再代偿。
  • 需要模型和生物标志物来识别这些候选者以优化 deceased donor 肝源的使用。

研究设计与样本

  • 回顾性队列研究,使用美国器官共享联合网络(United Network of Organ Sharing)数据库,纳入2002-2022年成人肝移植等待者共120451例。
  • 按时间段分为2002-2008年34444例、2009-2015年38296例、2016-2022年47711例。

主要发现

  • 共7196例(6.2%)因肝病改善被移除,三个时间段分别为5.6%、7.2%、5.3%(Armitage趋势检验P<0.001)。
  • 各病因移除率:酒精相关肝病(ALD n=41647)8.1%、丙型肝炎病毒(HCV n=38797)5.8%、自身免疫性肝病(n=12131)4.0%、代谢相关脂肪性肝炎(MASH n=22162)3.9%、乙型肝炎病毒(HBV n=3027)3.1%、代谢性肝病(MLD n=2687)3.1%。
  • Fine-Gray模型中,与代谢性肝病相比,一年时移除的亚风险比(95%CI):ALD 3.47(31.6-3.81)、HBV 3.44(2.96-3.99),P<0.001。
  • 7196例移除中,5750例进入名单时为失代偿,567例(9.9%)出现再代偿;各病因再代偿率:HBV 19.5%、MLD和自身免疫性肝病16.6%、ALD 9.9%、HCV 8.6%、MASH 6.9%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Data are limited regarding etiology-specific trends for delisting and recompensation for liver disease improvement among liver transplantation (LT)-listed candidates in the United States. METHODS AND RESULTS: A retrospective cohort (2002-2022) using United Network of Organ Sharing database examined etiology-specific trends for delisting and recompensation due to liver disease improvement among candidates listed for LT. Of 120,451 listings in adults, 34,444 (2002-2008), 38,296 (2009-2015), 47,711 (2016-2022) were analyzed. A total of 7,196 (6.2%) were delisted for liver disease improvement, with 5.6%, 7.2%, and 5.3% in 3 respective time periods, Armitage trend P < 0.001. Delisting for improvement of liver disease was 8.1%, 5.8%, 4.0%, 3.9%, and 3.1% among listings for alcohol-associated liver disease (ALD n = 41,647), hepatitis C virus infection (HCV n = 38,797), autoimmune (n = 12,131), metabolic-associated steatohepatitis (MASH n = 22,162), hepatitis B virus infection (HBV n = 3,027), and metabolic liver disease (MLD n = 2,687), respectively. One thousand one hundred twenty-two (15.6% or 0.9%) were delisted for improvement at 1 year with cumulative incidence competing for waitlist mortality and receipt of LT of 1.18, 1.17, 0.64, 0.59, 0.50, and 0.34 for ALD, HBV, HCV, MASH, MLD, and autoimmune, respectively. In a fine and gray model, compared with metabolic, subhazard ratio (95% confidence interval) on delisting at 1 year was 3.47 (31.6-3.81) and 3.44 (2.96-3.99), P < 0.001, for ALD and for HBV, respectively. Of 7,196 delisting for improvement, 567 of 5,750 (9.9%) decompensated at listing had recompensation, 19.5% for HBV, 16.6% for MLD and autoimmune, 9.9% ALD, 8.6% for HCV, and 6.9% for MASH. In a logistic regression model among delisted candidates for improved liver disease, HBV vs MASH etiology was associated with recompensation, 2.37 (1.40-4.03), P < 0.001. DISCUSSION: ALD and HBV are most frequent etiologies for delisting due to liver disease improvement. About 10% of delisted patients develop recompensation, with HBV etiology most likely to recompensate. Models and biomarkers are needed to identify these candidates for optimal use of deceased donor livers.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Singal AK, Panneerselvam D, Arab JP, et al. Delisting From Liver Transplant List for Improvement and Recompensation Among Decompensated Patients at One Year. Am J Gastroenterol. 2024. PMID: 39714037. doi:10.14309/ajg.0000000000003259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。